Consider a new way to treat onychomycosis
|
|
|
|
| |
For the treatment of onychomycosis of the toenail(s) due to Trichophyton rubrum and Trichophyton mentagrophytes1
|
|
| |
|
|
|
| |
How many onychomycosis patients in your practice could benefit from JUBLIA?
|
|
|
|
| |
Once-daily dosing with JUBLIA1
| • |
Integrated flow-through brush applicator1
|
| |
| • |
Applied once daily to affected nails for 48 weeks1
|
| |
| • |
Clear solution for topical application1
|
Please share these instructions with your patients for proper application of JUBLIA
| • |
Gently squeeze the bottle to apply one drop of JUBLIA onto the toenail
|
| |
| • |
Spread JUBLIA around the entire toenail, including
|
| |
| |
— |
Nail folds
|
| |
| |
— |
Toenail bed
|
| |
| |
— |
Hyponychium and the undersurface of the toenail plate
|
| |
| • |
Do not squeeze the bottle while spreading JUBLIA with the brush
|
JUBLIA tolerability1
JUBLIA is a topically applied solution with negligible† systemic absorption and no liver monitoring required1
| • |
The most common adverse reactions (incidence >1%) were (vs vehicle): ingrown toenail (2.3% vs 0.7%), application-site dermatitis (2.2% vs 0.2%), application-site vesicles (1.6% vs 0%), and application-site pain (1.1% vs 0.2%)1
|
| |
| • |
In vitro liver enzyme studies show that drug interactions are not expected1
|
| |
| • |
No need for patient counseling for potential liver toxicity1
|
| |
| • |
No need for liver function tests1
|
| |
| • |
JUBLIA is pregnancy category C, and should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus1
|
|
|
†
|
After application of JUBLIA once daily for 28 days, efinaconazole mean ± SD plasma Cmax on Day 28 was 0.67 ± 0.37 ng/mL and the mean ± SD AUC was 12.15 ± 6.91 ng*h/mL. JUBLIA should be used with caution in nursing mothers1
Proven effective to restore fungus-free healthy nails1
| • |
In Study 1, JUBLIA achieved 17.8% (117/656) complete cure vs 3.3% (7/214) with vehicle1
|
| |
| • |
In Study 2, JUBLIA achieved 15.2% (88/580) complete cure vs 5.5% (11/201) with vehicle1
|
| |
| • |
Complete cure defined as 0% involvement of the target nail in addition to mycological cure, defined as both negative fungal culture and negative KOH1
|
Study Design: In 2 identical, multicenter, randomized, parallel-group, double-blind, vehicle-controlled studies, patients with mild to moderate toenail distal lateral subungual onychomycosis (defined as 20%-50% clinical involvement of the target toenail, without dermatophytomas or matrix [lunula] involvement) were randomized to receive efinaconazole 10% solution or vehicle.2
|
|
|
|
| |
INDICATION
JUBLIA (efinaconazole) topical solution, 10% is indicated for the topical treatment of onychomycosis (tinea unguium) of the toenail(s) due to Trichophyton rubrum and Trichophyton mentagrophytes.
|
IMPORTANT SAFETY INFORMATION
|
| |
| • |
JUBLIA is for topical use only and is not for oral, ophthalmic, or intravaginal use.
|
| |
| • |
Patients should be instructed to contact their health care professional if a reaction suggesting sensitivity or severe irritation occurs.
|
| |
| • |
The most common adverse reactions (incidence >1%) were (vs vehicle): ingrown toenail (2.3% vs 0.7%), application-site dermatitis (2.2% vs 0.2%), application-site vesicles (1.6% vs 0%), and application-site pain (1.1% vs 0.2%).
|
| |
| • |
JUBLIA should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus, and should be used with caution in nursing women. The safety and effectiveness in pediatric patients have not been established.
|
Click here for Prescribing Information or visit www.JubliaRx.com.
|
|
| |
| * |
Offer valid only for commercially insured patients whose insurance covers JUBLIA. Commercially insured patients whose insurance does not cover JUBLIA may pay more. Not valid for patients reimbursed in whole or in part by federal health care programs, including Medicare, Medicaid, CHAMPUS, the Department of Veterans Affairs, state maternal and child health block grant programs under 42 U.S.C. 701 et. seq., state social service block grant programs under 42 U.S.C. section 1397 et. seq., or any other similar federal or state health care program. Void when prohibited by law, taxed, or restricted. Void outside the United States. See savings card for full eligibility terms and conditions here.
Patients with questions should call 855-264-0299.
|
References: 1. JUBLIA [prescribing information]. Bridgewater, NJ: Valeant Pharmaceuticals North America LLC; 2014. 2. Elewski BE, Rich P, Pollak R, et al. Efinaconazole 10% solution in the treatment of toenail onychomycosis: two phase III multicenter, randomized, double-blind studies. J Am Acad Dermatol. 2013;68(4):600-608.
Except as otherwise indicated, all product names, slogans, and other marks are trademarks of the Valeant family of companies.
|
|
| |
| |
|
You have the right to opt out of receiving unsolicited advertisements by e-mail. You may contact us with your opt-out request, along with the e-mail to which your request relates, by telephone at 1-877-540-6501, or by submitting your request to valeantorder@corpcomm.com. Opt-out requests will be honored within 10 business days of receipt. Please be sure to indicate the e-mail address to which your request relates and reason for opt-out.
© 2014 Valeant Pharmaceuticals North America LLC DM/JUB/14/0165
|
| |
|
|
|
